Linked Life Data

17845982

Source:http://linkedlifedata.com/resource/pubmed/id/17845982

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-9-11
pubmed:abstractText
A hallmark of locally advanced non-small cell lung cancer is its high local and systemic recurrence rates, ranging from 60% to 80%. Radiotherapy has shown its efficacy in controlling the tumor and in increasing overall survival, especially with combined sequential or concurrent chemotherapy to allow an anti-tumoral synergy. Gemcitabine, a new generation cytotoxic agent, is a potent radiosensitizer in vitro, and thus appears as a promising molecule in these multimodal therapeutic regimens. If the initial trial with gemcitabine and radiation produced unacceptable toxicities, lessons were learned from this study, and further phase I-II trials demonstrated that in a clinical trial setting, gemcitabine and radiation can be given safely, both in sequential and concurrent chemoradiation regimens, leading to high response rates and prolonged survival. Gemcitabine-radiation combination is currently integrated in phase III trials evaluating the optimal therapeutic sequence in locally advanced non-small cell lung cancer, and appears as one of the most promising therapeutic regimen in thoracic oncology.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1769-6917
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
94 Spec No Actualites
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S127-33
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Gemcitabine and radiotherapy in non-small cell lung cancer: dolce vita at last!].
pubmed:affiliation
Département de radiothérapie-oncologie, Centre hospitalier Lyon-Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite Cedex.
pubmed:publicationType
Journal Article, English Abstract, Review